Objective: To discuss the application effect of relaxing therapy with a decompression ball on anxieties of patients facing tooth extraction. Methods: Totally 72 dental anxieties patients facing tooth extraction were divided into control group and intervention group. Control group was carried out routine nursing, while intervention group was implemented relaxing therapy with a decompression ball on the basic of routine nursing. The changes of anxiety score, blood pressure and heart rate of both groups before and after intervention were compared. Besides, the cooperation of both groups during operation after intervention was compared, too. Results: After intervention, anxiety score of intervention group and control group was 9.92±3.20 and 12.44±3.32 respectively, indicating that the difference had statistical significance (t=-3.272, P<0.05). The difference value of anxiety score was 4.02±2.69 and the control group was 1.56±2.20. There was statistically significant difference of the two groups (t=4.273, P<0.01). The FRANKL behavior score of the cooperation degree during operation was 3.94±0.23 in intervention group and 3.67±0.48 in control group with statistically significant difference (t=3.136, P<0.05). Before and after intervention, there was no statistically significant difference regarding to systolic pressure, diastolic pressure and the heart rate (P>0.05). Conclusions Relaxing therapy with a decompression ball is beneficial to relieve the anxieties of dental patients facing tooth extraction, which can also improve the cooperation degree during operation and ensure the dental treatment carried out smoothly, thus it′s worth to be extended clinically.

The efficacy and safety of venetoclax combined with reduced dose HAD regimen in the treatment of newly diagnosed acute myeloid leukemia (AML) was investigated. From May 2022 to January 2023, a total of 25 patients with newly diagnosed AML were treated with venetoclax combined with reduced-dose HAD regimen as induction therapy. Accoding to the 2017 ELN recommendations, 13 (52.0%) in favoable, 3 (12.0%) in intemediate, and 9 (36.0%) in adverse. The ORR (CR rate+PR rate) was 88.0%, and the CR rate was 84.0%. By May 30, 2023, with a median follow-up of 9 months, 1 year overall survival, event-free survival, and relapse-free survival were 100%, 94.7%, and 94.7%, respectively. All patients received 1-5 cycles of consolidation therapy and two median cycles. Treatment with venetoclax and reduced dose of HAD regimen in the treatment of patients with newly diagnosed AML was high effective and safe.